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Abstract 
Background: Cerebral malaria remains a medical emergency with high mortality. Hypo-perfusion due to obstructed 
blood vessels in the brain is thought to play a key role in the pathophysiology of cerebral malaria leading to neurolog-
ical impairment, long-term neuro-cognitive sequelae and, potentially, death. Due to the rapid reversibility of vascular 
obstruction caused by sequestered Plasmodium falciparum, it is hypothesized that mild medical hypothermia—a 
standard intervention for other medical emergencies—may improve clinical outcome. This preclinical in vitro study 
was performed to assess the impact of mild hypothermia on parasite growth and the intrinsic activity of anti-malarials 
drugs.
Methods: Three laboratory-adapted clones and two clinical isolates were used for growth assays and standardized 
drug sensitivity assessments using the standard HRP2 assay. All assays were performed in parallel under normother-
mic (37 °C), mild hypothermic (32 °C), and hyperthermic (41 °C) conditions.
Results: Parasite growth was higher under standard temperature condition than under hypo- or hyperthermia 
(growth ratio 0.85; IQR 0.25–1.06 and 0.09; IQR 0.05–0.32, respectively). Chloroquine and mefloquine had comparable 
in vitro activity under mild hypothermic conditions (ratios for IC50 at 37 °C/32 °C: 0.88; 95 % CI 0.25–1.50 and 0.86; 
95 % CI 0.36–1.36, respectively) whereas dihydroartemisinin was more active under mild hypothermic conditions 
(ratio for IC50 at 37 °C/32 °C: 0.27; 95 % CI 0.19–0.27). Hyperthermia led by itself to almost complete growth inhibition 
and precluded further testing of the activity of anti-malarial drugs.
Conclusion: This preclinical evaluation demonstrates that mild medical hypothermia inhibits in vitro growth of P. 
falciparum and enhances the pharmacodynamic activity of artemisinin derivatives. Based on these preclinical pharma-
codynamic data, the further clinical development of mild medical hypothermia as adjunctive treatment to parenteral 
artesunate for cerebral malaria is warranted.
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Background
Cerebral malaria is a medical emergency requiring the 
immediate parenteral administration of effective anti-
malarial treatment in addition to best available intensive 
care. Cerebral malaria leads to high mortality and neuro-
logical and cognitive long-term sequelae even in settings 
where optimal intensive care is available [1]. The under-
lying pathophysiological mechanism is thought to be 
facilitated by the adherence of erythrocytes infected with 
Plasmodium falciparum trophozoites to the endothelial 
cell wall of small cerebral blood vessels with consecutive 
hypo-perfusion of the brain. This hypo-perfusion, which 
may lead to progressively increased intracranial pres-
sure, is, however, rapidly reversible by the administration 
of anti-malarial drugs [2]. Clearance of parasites from 
peripheral blood is usually achieved within 24 h in most 
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African settings, where the burden of severe malaria is 
highest—constituting a relatively short period of time for 
vulnerability of brain tissue [3].
Mild medical hypothermia is an established adjunctive 
treatment initiated immediately after successful resus-
citation from sudden cardiac arrest. It has been dem-
onstrated to improve neurological outcome in cardiac 
arrest survivors due to its ability to increase the permis-
sive period of hypoperfusion of the brain and to attenuate 
reperfusion injury [4, 5]. A target temperature of 32 °C is 
recommended for cardiac arrest patients and mild medi-
cal hypothermia is currently evaluated for other indica-
tions including ischemic stroke [4, 6].
Based on the analogy of the reversibility of hypoperfu-
sion of the brain in cardiac arrest and in cerebral malaria, 
it is hypothesized that mild medical hypothermia has 
the potential to improve neurological and cognitive out-
comes of patients treated for cerebral malaria. However, 
before testing this hypothesis in human patients, the 
preclinical evaluation of the effect of hypothermia on 
the growth of P. falciparum and the potential impact on 
the activity of anti-malarial drugs require investigation. 
Although hypothermia has been previously shown to 
reduce growth of P. falciparum [7, 8], this has not been 
investigated in the target range of mild medical hypother-
mia. Importantly, the effect of mild medical hypothermia 
on the pharmacodynamics of anti-malarial drugs has not 
been investigated before. This is particularly important 
as hypothermia may—at least in theory—lead to reduced 
anti-malarial activity due to reduced metabolic activity 
of the parasite and may thus put patients participating 
in such clinical trials at potential risk [9]. The aim of this 
study was, therefore, to evaluate the impact of hypother-
mia on the in  vitro growth of P. falciparum and on the 
in vitro activity of anti-malarial drugs.
Methods
Five P. falciparum strains were used for this in  vitro 
study, including three clones with distinct anti-malarial 
resistance patterns (7G8, DD2, 3D7) and two labora-
tory-adapted isolates from returning travellers from 
West Africa. Clone 7G8 is resistant to chloroquine 
and pyrimethamine. Clone DD2 shows resistance to 
pyrimethamine, mefloquine and chloroquine. Clone 3D7 
is drug sensitive [10]. The laboratory-adapted strains 
were previously shown to exhibit high-level drug resist-
ance against chloroquine but are sensitive to meflo-
quine and artemisinin derivatives. Parasites were kept in 
continuous malaria culture until optimum growth was 
achieved prior to growth inhibition assays as described 
previously [11, 12].
Growth inhibition assays were performed using a mod-
ified HRP2-assay protocol [13, 14]. All growth assays 
were performed in parallel under identical conditions 
except for incubation temperature. Temperatures were 
set at 37, 41 and 32 °C using calibrated incubators. Cul-
ture plates were pre-dosed with ascending concentra-
tions of the anti-malarial drugs chloroquine diphosphate 
(Sigma C6628), mefloquine and dihydroartemisinin. 
Stock solutions (1 mg/ml) of drugs were prepared in eth-
anol and further diluted to the required final concentra-
tions (chloroquine 3200  nmol/l, mefloquine 160  nmol/l 
and dihydroartemisinin 16 nmol/l). Two-fold serial dilu-
tions were employed and drug-free controls were per-
formed in parallel.
Two-hundred microliter parasite culture with a para-
sitaemia of 0.01 % and haematocrit of 1.5 % were trans-
ferred to each of the drug-coated wells. All assays were 
performed in triplicate and negative controls were imme-
diately frozen at initiation of the incubation period.
Growth was assessed by detection of HRP2 concentra-
tions by ELISA using commercially available monoclonal 
antibodies (1 µg/ml of IgM antibody MPFM-55 and IgG 
MPFG-55P55A, Immunology Consultants Laboratory, 
Portland, OR, USA). Inhibitory concentrations (IC) were 
calculated using freely available software (IVART) [15]. 
To obtain relative growth rates, logistic growth curves 
were fitted to data points obtained by serial dilution of 
lysed cultures using a least square regression model. 
Logistic regression analysis was conducted using the “R” 
statistical package [16]. No ethical clearance was required 
for this in vitro study following regulations of the Ethics 
Committee of the Medical University of Vienna.
Results
Laboratory-adapted clones (n  =  3) and clinical isolates 
(n = 2) were cultured in vitro until optimal growth was 
achieved. All parasites were then subjected in parallel 
to growth and growth inhibition assays under normo-
thermic (37  °C), hyperthermia (41  °C) and mild hypo-
thermic (32  °C) conditions. All strains showed adequate 
growth under normothermic conditions as assessed by 
the increase of HRP2 concentrations in parasite culture 
(median increase 3.9; IQR 3–7.8). Hypothermia was asso-
ciated with a markedly reduced growth rate compared to 
normothermia (relative growth rate 0.85; IQR 0.25–1.06). 
Hyperthermia led to the highest inhibition of parasite 
growth (0.09; IQR 0.05–0.32); see (Table 1).
The anti-parasitic activity of the anti-malarial drugs 
chloroquine, dihydroartemisinin and mefloquine was 
assessed under the three respective temperature con-
ditions (Table  1). Chloroquine and mefloquine had 
comparable IC50 values at 32 and 37  °C (chloroquine: 
113  nmol/l; 95  % CI 2.8–224  nmol/l vs 137  nmol/l; 
95 % CI 84–191 nmol/l and mefloquine 15 nmol/l; 95 % 
CI 5–25  nmol/l and 16  nmol/l; 95  % CI 9–24  nmol/l, 
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respectively). However, dihydroartemisinin showed con-
siderably lower IC50 values under mild hypothermic 
conditions (0.3  nmol/l; 95  % CI 0.2–0.5  nmol/l vs 1.3; 
95 % CI 1.1–1.4 nmol/l; p < 0.01).
Discussion
This study demonstrates that mild hypothermia leads in 
itself to a considerable inhibition of parasite growth. This 
pharmacodynamic activity is independent of the action 
of anti-malarials and is therefore most likely unaffected 
by the presence of specific drug resistance. Interestingly, 
hyperthermia is associated with an even higher inhibi-
tion of in vitro parasite growth. However, hyperthermia 
is likely to increase the metabolic activity of brain tissue 
and therefore potentially leads to adverse outcome of 
cerebral malaria. Based on these data, the current clini-
cal practice of normalizing temperature mechanically or 
with the use of antipyretic drugs may ultimately prove 
deleterious based on the finding of maximum in  vitro 
parasite growth under normothermic temperature con-
ditions. While the inhibitory effect of hyperthermia and 
hypothermia has been described previously, this is the 
first systematic evaluation of mild medical hypothermia 
and its inhibitory effect on P. falciparum in the context of 
anti-malarial drugs. These preclinical findings are further 
corroborated by clinical observations of faster parasite 
clearance in human patients in the absence of antipyretic 
drugs [17, 18].
It is well established that the early administration of 
parenteral artesunate is the most important treatment of 
severe malaria [1]. In vitro data from this study indicate 
that the anti-malarial activity of artesunate and its active 
metabolite dihydroartemisinin may be enhanced in two 
ways by mild hypothermia—firstly by direct inhibition of 
parasite growth and secondly by an increased anti-malar-
ial activity of dihydroartemisinin when used under hypo-
thermic conditions. Based on these findings there is—at 
least from a pharmacodynamic perspective—no convinc-
ing evidence precluding the use of mild medical hypo-
thermia in the treatment of cerebral malaria patients. 
Whereas this study was performed with the concept of 
applying mild medical hypothermia in cerebral malaria, 
this pharmacodynamic activities may also apply to 
other forms of severe malaria. Similarly, the findings of 
retained or even increased anti-malarial activity as dem-
onstrated for mefloquine, chloroquine and dihydroarte-
misinin in this in vitro study may apply to other classes of 
anti-malarials.
This study is a preclinical pilot study and is not 
designed to address all potential issues in the context 
of the use of medical hypothermia in malaria patients. 
Particularly the effect of mild medical hypothermia on 
cytoadherence can be investigated further in preclinical 
studies. Importantly, immunological consequences of 
hypothermia cannot be fully addressed by such in  vitro 
experiments and the pharmacokinetics of anti-malarial 
drugs may potentially be altered by the use of mild medi-
cal hypothermia. These important aspects should there-
fore be diligently assessed in the context of the clinical 
development of hypothermia as adjunct treatment of cer-
ebral malaria. Finally, the sample size of this pilot study 
is limited and the in  vivo parasite reduction rate will 
therefore be an important outcome of future clinical tri-
als [19].
Table 1 In vitro growth of  Plasmodium falciparum and  inhibitory concentrations of  dihydroartemisinin chloroquine, 
and mefloquine under normo-, hypo- and hyperthermic conditions
IQR interquartile range, 95 % CI 95 % confidence intervals, CQ chloroquine, DHA dihydroartemisinin, MQ mefloquine
Ratio of growth rate 32 °C IQR 37 °C 41 °C IQR
Isolate 1 1.15 1 0.16
Isolate 2 0.97 1 0.48
DD2 0.22 1 0.04
3D7 0.85 1 0.07
7G8 0.28 1 0.09
Total 0.85 0.25–1.06 0.09 0.05–0.32
50 % inhibitory concentration of anti-malarial drugs (nmol/l and IQR)
CQ 32 °C CQ 37 °C DHA 32 °C DHA 37 °C MQ 32 °C MQ 37 °C
Isolate 1 75.0 (40.2–109.8) 141.3 (124.9–157.6) 0.36 (0.30–0.43) 1.14 (0.96–1.32) 11.9 (10.2–13.6) 14.3 (11.7–17.0)
Isolate 2 69.2 (55.7–82.8) 153.8 (130.1–177.5) 0.24 (0.17–0.31) 1.38 (1.19–1.57) 6.8 (5.1–8.6) 17.7 (15.9–19.4)
DD2 337.4 (235.0–439.8) 167.6 (139.3–195.9) 0.49 (0.36–0.63) 1.23 (1.05–1.41) 26.3 (17.0–35.6) 14.7 (11.3–18.1)
3D7 38.6 (26.8–50.5) 33.9 (23.1–44.6) 0.44 (0.32–0.55) 1.51 (1.37–1.65) 26.6 (19.9–33.3) 30.0 (27.0–33.0)
7G8 46.7 (25.8–67.5) 190.8 (178.4–203.1) 0.20 (0.16–0.24) 1.12 (1.03–1.20) 2.2 (1.9–2.4) 5.4 (4.4–6.4)
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The further development of mild therapeutic hypother-
mia may well continue directly in clinical trials in humans 
given the low predictability of animal models for cer-
ebral malaria [20]. Whereas the conduction of such pilot 
studies in high-resource settings may be a viable option, 
endemic regions may be more relevant given the overall 
burden of disease. Importantly, external mechanical cool-
ing of patients is feasible with relatively simple devices, 
including cooling blankets, but adequate monitoring 
of core temperature by oesophageal or urinary bladder 
probes is mandatory to avoid iatrogenic risks associated 
with hypothermia below 32 °C [4].
Conclusion
In summary, this in  vitro study provides evidence sup-
porting the clinical development of mild medical hypo-
thermia for the treatment of cerebral malaria. Future 
studies should include feasibility outcomes of the proce-
dure as well as pharmacodynamic and pharmacokinetic 
assessments associated with the use of mild medical 
hypothermia.
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